<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902022000201701</article-id>
<article-id pub-id-type="doi">10.29193/rmu.38.2.9</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hepatotoxicidad por metilprednisolona. Reporte de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Methylprednisolone-induced hepatotoxicity. A case report]]></article-title>
<article-title xml:lang="pt"><![CDATA[Hepatotoxicidade por metilprednisolona. Relato de um caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Taborda]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de León]]></surname>
<given-names><![CDATA[Yesika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Facal]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ASSE Hospital Maciel ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,ASSE Hospital Maciel ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Hospital Maciel]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>38</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902022000201701&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902022000201701&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902022000201701&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la hepatotoxicidad inducida por fármacos y otros agentes es una forma frecuente de injuria hepática, superando en algunos países a las hepatitis virales. La presentación es variable, desde una alteración aislada del funcional hepático hasta formas graves con fallo hepático agudo fulminante. Se presenta un caso de lesión hepática aguda luego de un ciclo corto con altas dosis de metilprednisolona intravenosa.  Caso clínico:  sexo femenino, 45 años. Antecedentes personales de esclerosis múltiple, con último empuje 40 días previo a la consulta, tratada con bolos de metilprednisolona intravenosa. Consulta por ictericia de una semana de evolución, dolor abdominal, vómitos, anorexia, astenia y adinamia en el último mes. De la paraclínica se destaca: hiperbilirrubinemia mixta, elevación de las transaminasas, tiempo de protrombina descendido. Se descarta etiología viral, autoinmune y metabólica. Se plantea hepatotoxicidad por metilprednisolona que se confirma con la evolución favorable, y normalización a los 3 meses del enzimograma hepático y tiempo de protrombina tras la suspensión del tratamiento con metilprdnisolona.  Discusión:  el primer paso para el diagnóstico de hepatotoxicidad es descartar otras causas de injuria hepática. En segundo lugar, se debe demostrar la relación temporal entre la exposición al fármaco y el daño hepático. Por último, la suspensión del medicamento suele acompañarse de mejoría del cuadro clínico y analítico. Para diagnosticar esta entidad es necesario tener un alto índice de sospecha. El tratamiento con dosis altas de metilprednisolona puede inducir hepatitis severa que recurre con la re-exposición a la droga. Los pacientes con enfermedades autoinmunes tienen mayor riesgo de desarrollar hepatotoxicidad, lo que plantea un desafío terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  drug induced hepatotoxicity and toxicity induced by other agents is a frequent form of liver injury, accounting for larger number of cases than viral hepatitis in some countries. Presentation may be variable, from an isolated alteration in the liver function test to severe forms of acute fulminant liver failure. The study presents a case of severe liver injury following a short cycle with high doses of intravenous methylprednisolone.  Clinical case:  45 year-old female patient. Personal history of multiple sclerosis, with relapse 40 days prior to the consultation, treated with intravenous methylprednisolone. The patient consulted for jaundice with one week of evolution, abdominal pain, vomiting, anorexia, asthenia, and adynamia in the last month. Paraclinical tests find mixed hyperbilirubinemia, increased transaminases and decreased prothrombin time (PT). Viral, autoimmune and metabolic etiology are ruled out and a hypothesis is made for methylprednisolone-induced hepatotoxicity. The latter is confirmed and evolution is favorable, liver enzymogram being normal after three months, the same as the prothrombin time upon the interruption of methylprednisolone therapy.  Discussion:  the first step to diagnose hepatotoxicity is excluding other causes of liver injury. Next, the temporal relationship between drug exposure and liver injury needs to be demonstrated. Last, withdrawing the drug is usually accompanied by clinical and tests improvement. A high degree of suspicion is necessary to diagnose this condition. Therapies with high doses of methylprednisolone may cause severe hepatitis, and it is recurrent upon re-exposure to the drug. Patients with autoimmune diseases have greater risks of developing hepatotoxicity, what results in a therapeutic challenge.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  a hepatotoxicidade induzida por drogas e outros agentes é uma forma frequente de lesão hepática, superando as hepatites virais em alguns países. A apresentação é variável, desde uma alteração isolada da função hepática até formas graves com insuficiência hepática aguda fulminante. Um caso de lesão hepática aguda após um curto curso de metilprednisolona intravenosa em altas doses é apresentado.  Caso clínico: sexo feminino, 45 anos. Antecedentes pessoais de esclerose múltipla, com último impulso 40 dias antes da consulta, tratados com bolus de metilprednisolona endovenosa. Consulta por icterícia de uma semana de evolução, dor abdominal, vômitos, anorexia, astenia e adinamia no último mês. Dos exames paraclínicos, destacam-se: hiperbilirrubinemia mista, transaminases elevadas, tempo de protrombina diminuído. A etiologia viral, autoimune e metabólica é descartada. Foi sugerida hepatotoxicidade por metilprednisolona, confirmada pela evolução favorável, e normalização aos 3 meses da enzima hepática e do tempo de protrombina após a interrupção do tratamento com metilprednisolona.  Discussão:  o primeiro passo no diagnóstico de hepatotoxicidade é descartar outras causas de lesão hepática. Em segundo lugar, a relação temporal entre a exposição à droga e o dano hepático deve ser demonstrada. Por fim, a suspensão do medicamento costuma ser acompanhada de melhora do quadro clínico e analítico. Para diagnosticar esta entidade é necessário ter um alto índice de suspeição. O tratamento com altas doses de metilprednisolona pode induzir hepatite grave que se repete na reexposição ao medicamento. Pacientes com doenças autoimunes apresentam risco aumentado de desenvolver hepatotoxicidade, o que representa um desafio terapêutico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hepatotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[Metilprednisolona]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis múltiple]]></kwd>
<kwd lng="en"><![CDATA[Hepatotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Metilprednisolona]]></kwd>
<kwd lng="en"><![CDATA[Multiple sclerosis]]></kwd>
<kwd lng="pt"><![CDATA[Hepatotoxicidade]]></kwd>
<kwd lng="pt"><![CDATA[Metilprednisolona]]></kwd>
<kwd lng="pt"><![CDATA[Esclerose múltipla]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostapowicz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schiødt]]></surname>
<given-names><![CDATA[FV]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Davern]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2002</year>
<volume>137</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>947-54</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmerman]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced liver disease]]></article-title>
<source><![CDATA[Clin Liver Dis]]></source>
<year>2000</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-96</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bessone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tagle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arrese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parana]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez-Sánchez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced liver injury: a management position paper from the Latin American Association for Study of the liver]]></article-title>
<source><![CDATA[Ann Hepatol]]></source>
<year>2021</year>
<volume>24</volume>
<page-range>100321</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Polson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davern]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lalani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hynan]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2005</year>
<volume>42</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1364-72</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivero Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Riesco]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicidad hepática recurrente secundaria a metilprednisolona intravenosa]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[López San Román]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arranz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2008</year>
<volume>100</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>720-3</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zoubek]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Pinazo-Bandera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega-Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver injury after methylprednisolone pulses a disputable cause of hepatotoxicity. A case series and literature review]]></article-title>
<source><![CDATA[United European Gastroenterol J]]></source>
<year>2019</year>
<volume>7</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>825-37</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marinó]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morabito]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Altea]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrogini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brunetto]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves]]></article-title>
<source><![CDATA[J Endocrinol Invest]]></source>
<year>2005</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>280-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Delgado]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Forrellat Barrios]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valledor-Tristá]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lavaut-Sánchez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera García]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemocromatosis hereditaria tipo I: a propósito de cuatro casos confirmados]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2014</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-67</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[León-González]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Zárate-Sánchez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Trujillo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Bistrain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios-López]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemocromatosis. Revisión de la literatura y presentación de un caso ilustrativo]]></article-title>
<source><![CDATA[Rev Méd Hosp Gen Méx]]></source>
<year>2001</year>
<volume>64</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>246-50</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>European Association for the Study of the Liver</collab>
<article-title xml:lang=""><![CDATA[EASL Clinical Practice Guidelines: Drug-induced liver injury]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2019</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1222-61</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Teschke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RUCAM in drug and herb induced liver injury: the update]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2015</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<source><![CDATA[LiverTox: Clinical and Research Information on Drug-Induced Liver Injury]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Bethesda, MD ]]></publisher-loc>
<publisher-name><![CDATA[National Institute of Diabetes and Digestive and Kidney Diseases]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D`Agnolo]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Drenth]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature]]></article-title>
<source><![CDATA[Neth J Med]]></source>
<year>2013</year>
<volume>71</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>199-202</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nociti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Biolato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Fino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bianco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Losavio]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients]]></article-title>
<source><![CDATA[Brain Behav]]></source>
<year>2018</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adamec]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlovic]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pavicic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ruska]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Habek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis]]></article-title>
<source><![CDATA[Mult Scler Relat Disord]]></source>
<year>2018</year>
<volume>25</volume>
<numero>2015</numero>
<issue>2015</issue>
<page-range>43-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
